专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0123577A3 HYBRID OR CHIMERIC POLYNUCLEOTIDES, PROTEINS, AND COMPOSITIONS COMPRISING HEPATITIS B VIRUS SEQUENCES 审中-公开
标题翻译：包含乙型肝炎病毒序列的杂合或嵌合多核苷酸，蛋白质和组合物
公开(公告)号：WO0123577A3
公开(公告)日：2001-05-17
申请号：PCT/EP0009900
申请日：2000-09-29
申请人： PASTEUR INSTITUT , FIRAT HUESEYIN , LEMONNIER FRANCOIS , LANGLADE DEMOYEN PIERRE , MICHEL MARIE LOUISE , SUHRBIER ANDREAS A
发明人： FIRAT HUESEYIN , LEMONNIER FRANCOIS , LANGLADE-DEMOYEN PIERRE , MICHEL MARIE-LOUISE , A SUHRBIER ANDREAS
IPC分类号： A61K48/00 , C07K14/02 , C12N7/01 , C12N15/36 , C12N15/62
CPC分类号： C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/292 , A61K48/00 , A61K2039/5258 , A61K2039/57 , C07K2319/00 , C07K2319/40 , C12N2730/10122 , C12N2730/10134
摘要： H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. Co-injection of a helper peptide enhanced most CTL responses. In contrast, classical HLA class I transgenic mice which still express their own class I molecules did not, in most cases, develop H.A.-A2.1-restricted CTL responses under the same experimental conditions. Different monoepitopic immunization strategies of acceptable clinical usage were compared in HHD mice. Recombinant Ty-virus-like particles, or DNA encoding epitopes fused to the hepatitis B virus middle envelope protein gave the best results. Using this latter approach and a melanoma-based polyepitope construct, CTL responses against five distinct epitopes could be elicited simultaneously in a single animal. Thus, HHD mice provide a versatile animal model for preclinical evaluation of peptide-based cancer immunotherapy.
摘要翻译： H-2 I类阴性HLA-A2.1转基因HHD小鼠用于HLA-A2.1限制性人肿瘤相关CTL表位免疫原性的比较评估。在注射到IFA小鼠中的这些表位肽之间建立了等级，其与它们结合和稳定HLA-A2.1分子的能力在全局上相关。共注射辅助肽增强了大多数CTL应答。相反，仍然表达它们自己的I类分子的经典HLA I类转基因小鼠在大多数情况下在相同的实验条件下不发展H.A.-A2.1限制性CTL应答。在HHD小鼠中比较了可接受的临床使用的不同单表位免疫策略。重组的Ty-病毒样颗粒或编码与乙型肝炎病毒中间包膜蛋白融合的表位的DNA给出最佳结果。使用后一种方法和基于黑素瘤的多表位构建体，可以在单一动物中同时引发针对五种不同表位的CTL应答。因此，HHD小鼠提供了用于基于肽的癌症免疫疗法的临床前评估的通用动物模型。

2. 发明申请

WO2003029285A3 IDENTIFICATION OF CD8 EPITOPES FROM HIV-1 PROTEINS FOR PREVENTION AND THERAPY OF HIV INFECTIONS 审中-公开
公开(公告)号：WO2003029285A3
公开(公告)日：2003-04-10
申请号：PCT/IB2002/004576
申请日：2002-09-27
申请人： INSTITUT PASTEUR , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , CARDINAUD, Sylvain , HABEL, André , LANGLADE-DEMOYEN, Pierre , LEMONNIER, François
发明人： CARDINAUD, Sylvain , HABEL, André , LANGLADE-DEMOYEN, Pierre , LEMONNIER, François
IPC分类号： C07K14/16
摘要： The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications.Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof.The invention also relates to antibodies directed against said peptides.

3. 发明申请

WO1996001891A1 METHOD FOR GENERATING A POPULATION OF CELLS HAVING A HIGH SURFACE DENSITY OF A MHC MOLECULE-ASSOCIATED SPECIFIC EXOGENOUS PEPTIDE, AND CELL POPULATION 审中-公开
标题翻译：用于产生具有MHC分子相关特异性外源性细胞和细胞群体的高表面密度的细胞群体的方法
公开(公告)号：WO1996001891A1
公开(公告)日：1996-01-25
申请号：PCT/FR1995000907
申请日：1995-07-06
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT PASTEUR , LANGLADE DEMOYEN, Pierre , KOURILSKY, Philippe , ABASTADO, Jean-Pierre
发明人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT PASTEUR
IPC分类号： C12N05/06
CPC分类号： C07K14/70539 , A61K39/0011 , A61K2039/5154 , A61K2039/5158 , Y02A50/412
摘要： A method for generating a population of cells having a high surface density of an MHC molecule-associated specific exogenous peptide. A population of living non-tumour mammalian cells, particularly human peripheral blood lymphocyte splenic cells, ganglion cells, cord blood cells or placental cells, wherein said cells have a surface density of one MHC molecule-associated specific exogenous peptide with the same allele restriction as MHC molecules, whic h restriction is substantially higher than that of the corresponding cells that express said native MHC molecule-associated exogenous peptide.
摘要翻译：一种用于产生具有MHC分子相关特异性外源肽的高表面密度的细胞群的方法。活的非肿瘤哺乳动物细胞群，特别是人外周血淋巴细胞脾细胞，神经节细胞，脐带血细胞或胎盘细胞，其中所述细胞具有一个MHC分子相关特异性外源肽的表面密度，具有与 MHC分子的限制性明显高于表达所述天然MHC分子相关外源肽的相应细胞的限制。

4. 发明申请

WO2003029285A2 IDENTIFICATION OF NEW CD8 EPITOPES FROM HIV-1 PROTEINS WITH THERAPEUTICAL AND VACCINAL PROPERTIES AGAINST HIV INFECTIONS 审中-公开
标题翻译：从HIV-1蛋白鉴定新的CD8抗体，具有抗艾滋病毒感染的治疗和真菌性质
公开(公告)号：WO2003029285A2
公开(公告)日：2003-04-10
申请号：PCT/IB2002/004576
申请日：2002-09-27
申请人： INSTITUT PASTEUR , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE , CARDINAUD, Sylvain , HABEL, André , LANGLADE-DEMOYEN, Pierre , LEMONNIER, François
发明人： CARDINAUD, Sylvain , HABEL, André , LANGLADE-DEMOYEN, Pierre , LEMONNIER, François
IPC分类号： C07K14/16
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/505 , A61K2039/515 , A61K2039/53 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , G01N33/56988
摘要： The invention relates to the identification and the selection of CTL epitopes able to induce a protection against an HIV infection. More particularly, the invention is concerned with peptides and nucleic acid sequence coding for these peptides derived from HIV-1 proteins such as GAG, POL, ENV, VIF, TAT, VPU, REV and their applications.Preferably the immunogenic peptides are selected from the group consisting of SEQ ID NOs:1 to 18 and functional derivatives thereof.The invention also relates to antibodies directed against said peptides.
摘要翻译：本发明涉及能够诱导针对HIV感染的保护的CTL表位的鉴定和选择。更具体地，本发明涉及编码这些衍生自HIV-1蛋白如GAG，POL，ENV，VIF，TAT，VPU，REV的肽的肽和核酸序列及其应用。优选地，免疫原性肽选自由SEQ ID NO：1至18组成的组及其功能衍生物。本发明还涉及针对所述肽的抗体。

5. 发明申请

WO1997044667A2 METHOD FOR USING PEPTIDE COMPLEXES/MAJOR HISTOCOMPATIBILITY COMPLEX TO OBTAIN OR PURIFY ANTIGEN-SPECIFIC T CELLS AND TO STIMULATE T CELLS 审中-公开
标题翻译：使用肽复合物/主要组氨酸复合物获得或纯化抗原特异性T细胞并刺激T细胞的方法
公开(公告)号：WO1997044667A2
公开(公告)日：1997-11-27
申请号：PCT/FR1997000892
申请日：1997-05-21
申请人： INSTITUT PASTEUR , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , LANGLADE-DEMOYEN, Pierre , LONE, Yu-Chun , KOURILSKY, Philippe , ABASTADO, Jean-Pierre
发明人： INSTITUT PASTEUR , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
IPC分类号： G01N33/569
CPC分类号： C07K14/005 , C07K14/70539 , C12N2760/16122 , G01N33/56977 , G01N33/574
摘要： The invention features methods for using MHC/peptide complexes. The successful peptide-specific T lymphocyte purification by adsorption on a solid support coupled with a high density of MHC recombinant molecules, charged with a single peptide is disclosed. This method has enabled the isolating, purifying and quantifying of tumoral specific T lymphocytes, from peritoneal exudate and tumor-infiltrating lymphocytes. These purified T lymphocyte populations can be further multiplied in vitro. The resulting cells show a superior cytotoxic activity and an enhanced anti-tumoral action by re-injection in the tumor carrier. This novel approach is important for analysing the T lymphocytes repertoire at the peptide specificity level and to improve novel T lymphocyte adoptive immunotherapy based therapeutic treatments. Further, the MHC/peptide specific complexes can induce or stimulate peptide-specific T lymphocytes. Thus are also disclosed methods to induce cytotoxic T lymphocytes (CTL). These CTL can be used in turn to fight tumoral cell growth in vitro or in vivo. The MHC recombinant molecule charged with a single peptide can be effectively used in polymer form to stimulate specific immune response ex vivo or in vivo after being injected in man or animal.
摘要翻译：本发明的特征在于使用MHC /肽复合物的方法。公开了通过在固体支持物上吸附成功的肽特异性T淋巴细胞，其与高密度的MHC重组分子偶联，装载有单一肽。该方法能够从腹膜渗出液和肿瘤浸润淋巴细胞中分离，纯化和定量肿瘤特异性T淋巴细胞。这些纯化的T淋巴细胞群可以进一步在体外倍增。所得细胞通过在肿瘤载体中重新注射显示出优异的细胞毒性活性和增强的抗肿瘤作用。这种新方法对于分析肽特异性水平的T淋巴细胞谱和改善基于T淋巴细胞过继免疫治疗的治疗方法是重要的。此外，MHC /肽特异性复合物可以诱导或刺激肽特异性T淋巴细胞。因此，还公开了诱导细胞毒性T淋巴细胞（CTL）的方法。这些CTL可以依次用于在体外或体内抗肿瘤细胞生长。带有单个肽的MHC重组分子可以有效地以聚合物形式使用，以便在人或动物注射后离体或体内刺激特异性免疫应答。

6. 发明申请

WO2007014740A3 POLYNUCLEOTIDES ENCODING MHC CLASS I-RESTRICTED HTERT EPITOPES, ANALOGUES THEREOF OR POLYEPITOPES 审中-公开
标题翻译：编码MHC I类限制性HITT表位的多核苷酸，其类似物或多聚肽
公开(公告)号：WO2007014740A3
公开(公告)日：2007-05-03
申请号：PCT/EP2006007571
申请日：2006-07-31
申请人： PASTEUR INSTITUT , INST NAT SANTE RECH MED , LANGLADE-DEMOYEN PIERRE , GARCIA PONS FRANCISCO , ADOTEVI OLIVIER , CARDINAUD SYLVAIN , NEUVEUT CHRISTINE
发明人： LANGLADE-DEMOYEN PIERRE , GARCIA PONS FRANCISCO , ADOTEVI OLIVIER , CARDINAUD SYLVAIN , NEUVEUT CHRISTINE
IPC分类号： C12N9/12
CPC分类号： C12N9/1276 , A61K38/00 , A61K39/0011 , A61K2039/572 , C12N9/1241
摘要： This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
摘要翻译：本发明涉及抗癌疗法领域，并涉及从人端粒酶逆转录酶（hTERT）衍生的免疫原性肽的鉴定。本发明涉及编码限于MHC I类分子的hTERT表位，其类似物和含有此类表位和/或类似物的多表位的多核苷酸。也包括在本发明中的载体和包含这种多核苷酸的细胞中。本发明还涉及包含hTERT多肽，相应的多核苷酸，载体和细胞的组合物，用于治疗和/或预防癌症。

7. 发明申请

WO2007014740A2 POLYNUCLEOTIDES ENCODING MHC CLASS I-RESTRICTED HTERT EPITOPES, ANALOGUES THEREOF OR POLYEPITOPES 审中-公开
标题翻译：编码MHC类限制性HTERT抗体的多核苷酸，其模拟物或多聚体
公开(公告)号：WO2007014740A2
公开(公告)日：2007-02-08
申请号：PCT/EP2006/007571
申请日：2006-07-31
申请人： INSTITUT PASTEUR , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , LANGLADE-DEMOYEN, Pierre , GARCIA PONS, Francisco , ADOTEVI, Olivier , CARDINAUD, Sylvain , NEUVEUT, Christine
发明人： LANGLADE-DEMOYEN, Pierre , GARCIA PONS, Francisco , ADOTEVI, Olivier , CARDINAUD, Sylvain , NEUVEUT, Christine
IPC分类号： C12N9/12
CPC分类号： C12N9/1276 , A61K38/00 , A61K39/0011 , A61K2039/572 , C12N9/1241
摘要： This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
摘要翻译：本发明涉及抗癌治疗领域，以及鉴定源自人端粒酶逆转录酶（hTERT）的免疫原性肽。本发明涉及编码限于MHC I类分子的hTERT表位的多核苷酸，其类似物和含有这些表位和/或类似物的多表位。也包括在本发明中，包含这种多核苷酸的载体和细胞。本发明还涉及包含用于治疗和/或预防癌症的hTERT多肽，相应的多核苷酸，载体和细胞的组合物。

8. 发明申请

WO0127291A9 DESIGN OF A POLYEPITOPIC CONSTRUCT FOR THE INDUCTION OF HLA-A2.1 RESTRICTED HIV 1 SPECIFIC CTL RESPONSES USING HHD MICE 审中-公开
标题翻译：用于诱导HLA-A2.1限制性HIV的多功能构建体的设计使用HHD MICE的特异性CTL应答
公开(公告)号：WO0127291A9
公开(公告)日：2002-09-06
申请号：PCT/EP0009902
申请日：2000-09-29
申请人： PASTEUR INSTITUT , FIRAT HUESEYIN , LEMONNIER FRANCOIS , LANGLADE-DEMOYEN PIERRE
发明人： FIRAT HUESEYIN , LEMONNIER FRANCOIS , LANGLADE-DEMOYEN PIERRE
IPC分类号： A61K39/00 , C07K14/02 , C07K14/16 , C12N15/62 , A61K39/21 , A61K39/29
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/53 , C07K2319/00 , C07K2319/40 , C12N15/62 , C12N2730/10122 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： H-2 class I negative, HLA-A2.1 transgenic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumour-associated CTL epitopes and HIV 1-derived epitopes. A hierarchy was established among these epitopic peptides injected into mice in IFA which correlates globally with their capacity to bind and stabilize HLA-A2.1 molecules. A tyrosine substitution in position 1 of the HIV 1-derived epitopic peptides, which increases both their affinity for and their HLA-A2.1 molecule stabilizing capacity, was introduced in a significant proportion of them. DNA immunizations were performed using a construct comprising nucleic acids encoding the epitopes inserted into the pre-S2 segment of the hepatitis B middle glycoprotein. CTL responses against most of the inserted epitopes could be elicited simultaneously in a single animal.
摘要翻译：使用H-2类I阴性，HLA-A2.1转基因HHD小鼠进行HLA-A2.1限制性人肿瘤相关CTL表位和HIV1-衍生表位的免疫原性的比较评估。在IFA中注射到小鼠中的这些表位肽之间建立了等级关系，其与其与结合和稳定HLA-A2.1分子的能力全球相关。在其中很大一部分引入了HIV 1衍生的表位肽的位置1中的酪氨酸取代，其增加了它们对HLA-A2.1分子稳定能力的亲和力和HLA-A2.1分子稳定能力。使用构建体进行DNA免疫，所述构建体包含编码插入到乙型肝炎中间糖蛋白的前S2区段内的表位的核酸。大多数插入的表位的CTL反应可以在单个动物中同时引发。

9. 发明申请

WO9744667A3 Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific T cells and to stimulate cells 审中-公开
标题翻译：使用肽复合物/主要组织相容性复合物获得或纯化抗原特异性T细胞并刺激细胞的方法
公开(公告)号：WO9744667A3
公开(公告)日：1998-03-19
申请号：PCT/FR9700892
申请日：1997-05-21
申请人： PASTEUR INSTITUT , INST NAT SANTE RECH MED , LANGLADE-DEMOYEN PIERRE , LONE YU-CHUN , KOURILSKY PHILIPPE , ABASTADO JEAN-PIERRE
发明人： LANGLADE-DEMOYEN PIERRE , LONE YU-CHUN , KOURILSKY PHILIPPE , ABASTADO JEAN-PIERRE
IPC分类号： C07K14/11 , C07K14/74 , G01N33/569 , G01N33/574 , C07K14/705
CPC分类号： C07K14/005 , C07K14/70539 , C12N2760/16122 , G01N33/56977 , G01N33/574
摘要： The invention features methods for using MHC/peptide complexes. The successful peptide-specific T lymphocyte purification by adsorption on a solid support coupled with a high density of MHC recombinant molecules, charged with a single peptide is disclosed. This method has enabled the isolating, purifying and quantifying of tumoral specific T lymphocytes, from peritoneal exudate and tumor-infiltrating lymphocytes. These purified T lymphocyte populations can be further multiplied in vitro. The resulting cells show a superior cytotoxic activity and an enhanced anti-tumoral action by re-injection in the tumor carrier. This novel approach is important for analysing the T lymphocytes repertoire at the peptide specificity level and to improve novel T lymphocyte adoptive immunotherapy based therapeutic treatments. Further, the MHC/peptide specific complexes can induce or stimulate peptide-specific T lymphocytes. Thus are also disclosed methods to induce cytotoxic T lymphocytes (CTL). These CTL can be used in turn to fight tumoral cell growth in vitro or in vivo. The MHC recombinant molecule charged with a single peptide can be effectively used in polymer form to stimulate specific immune response ex vivo or in vivo after being injected in man or animal.

10. 发明申请

WO9718232A3 PEPTIDES DERIVED FROM THE ONCOGENE PROTEINE BCR-ABL EXPRESSED BY LEUKEMIC CELLS AND UTILISATION THEREOF FOR THE THERAPY OF HUMAN LEUKEMIAE 审中-公开
标题翻译：由白血病细胞表达的蛋白BCR-ABL衍生的肽和人类淋巴细胞治疗的利用
公开(公告)号：WO9718232A3
公开(公告)日：1997-07-03
申请号：PCT/FR9601799
申请日：1996-11-14
申请人： INST NAT SANTE RECH MED , PASTEUR INSTITUT , LANGLADE DEMOYEN PIERRE , ABASTADO JEAN PIERRE , KOURILSKY PHILIPPE
发明人： LANGLADE-DEMOYEN PIERRE , ABASTADO JEAN-PIERRE , KOURILSKY PHILIPPE
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C07K14/82 , C12N5/08 , C07K
CPC分类号： C07K14/47 , A61K38/00 , A61K48/00 , C07K14/82
摘要： The invention relates to peptides capable of inducing a response of human cytotoxic T lymphocytes (CTL) specifically directed against cells expressing the fusion protein BCR-ABL.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式